The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3]. © 2009 Springer-Verlag New York.
CITATION STYLE
Rehberg, S., Enkhbaatar, P., & Traber, D. L. (2007). Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine. In Yearbook of Intensive Care and Emergency Medicine 2009 (pp. 498–510). Springer New York. https://doi.org/10.1007/978-0-387-92278-2_47
Mendeley helps you to discover research relevant for your work.